Solid Biosciences Inc.

Aug 6, 2026

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported its financial results for Q2 2026, highlighting progress in its clinical trials for SGT-003 and SGT-212. The company plans to meet with the FDA to discuss SGT-003's data and potential accelerated approval. Additionally, the Phase 3 IMPACT DUCHENNE trial has commenced, and initial data from the Friedreich's Ataxia trial is anticipated in early 2027. Despite a growing cash position, the company reported a net loss of $54.8 million for the quarter.

Jun 25, 2026

Letter to the Duchenne Community

Solid Biosciences provides an update on SGT-003, their investigational gene therapy for Duchenne muscular dystrophy, during the PPMD conference. As of June 22, 2026, 53 boys have been dosed in the INSPIRE DUCHENNE trial, with no serious safety concerns reported. The company is also advancing into the Phase 3 IMPACT DUCHENNE trial, aiming for global regulatory authorizations.

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 1, 2026

Solid Biosciences Inc. has announced the grant of 6,580 restricted stock units (RSUs) to a newly hired employee. This grant is part of the company's 2024 Inducement Stock Incentive Plan and is intended to incentivize the employee's acceptance of the job. The RSUs will vest over four years, contingent on the employee's continued service.

Jun 1, 2026

Solid Biosciences to Participate at Upcoming Investor Conferences

Solid Biosciences Inc. has announced its participation in two upcoming investor conferences in June 2026. The presentations will be made by President and CEO Bo Cumbo, showcasing the company's advancements in precision genetic medicines for rare neuromuscular and cardiac diseases. The live webcasts of the presentations will be accessible on the company's website for interested investors and stakeholders. This engagement aims to highlight Solid's commitment to innovative gene therapies and ongoing developments in its pipeline.

May 13, 2026

Solid Biosciences Reports First Quarter 2026 Financial Results and Provides Business Updates

Solid Biosciences reported its Q1 2026 financial results, highlighting significant advancements in its clinical trials for Duchenne muscular dystrophy and Friedreich's ataxia. The company has initiated the Phase 3 IMPACT DUCHENNE trial and received positive regulatory feedback from the EMA. Additionally, Solid maintains a robust cash position, supporting its ongoing development efforts.

May 7, 2026

Solid Biosciences Doses First Participant In Phase 3 Impact Duchenne Clinical Trial Evaluating SGT-003 In Duchenne Muscular Dystrophy

May 4, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026

Solid Biosciences Inc. has announced the grant of 8,070 restricted stock units to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. This grant, which vests over four years, is intended to incentivize the new employee's acceptance of the position. The company continues to advance its pipeline of gene therapies targeting rare neuromuscular and cardiac diseases.

May 1, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635 c 4

Apr 30, 2026

Solid Biosciences to Showcase a Large Presence at the 29th Annual Meeting of the American Society of Gene and Cell Therapy

Solid Biosciences Inc. will present its largest scientific program at the 29th Annual Meeting of the ASGCT, featuring 16 presentations including 5 oral and 11 poster presentations. The event highlights the company's advancements in gene therapies for neuromuscular and cardiac diseases, showcasing their commitment to innovation and clinical development. CEO Bo Cumbo emphasized the significance of this meeting for Solid's growth and scientific rigor.

Apr 28, 2026

Solid Biosciences Announces Receipt of European Commission Orphan Drug Designation for SGT-003 for the Treatment of Duchenne Muscular Dystrophy

Solid Biosciences has announced that the European Commission granted Orphan Drug Designation for SGT-003, aimed at treating Duchenne muscular dystrophy. This designation reflects the drug's potential to address significant unmet medical needs. SGT-003 is currently being evaluated in two clinical trials, INSPIRE DUCHENNE and IMPACT DUCHENNE, as part of a broader international development strategy.

Mar 19, 2026

Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Solid Biosciences Provides Interim Positive Clinical Update

Mar 9, 2026

▲ +18.8%on this newsshared move

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Inc. will present its investigational gene therapies SGT-003 and SGT-212 at the 2026 MDA Clinical & Scientific Conference in Orlando. The presentations will cover the Phase 1/2 study of SGT-003 for Duchenne muscular dystrophy and the investigational gene therapy SGT-212 for Friedreich’s ataxia. The conference will take place from March 8-11, 2026.

Mar 9, 2026

▲ +18.8%on this newsshared move

Solid Biosciences Announces Oversubscribed $240 Million Private Placement

Solid Biosciences Inc. has announced a successful oversubscribed private placement, raising approximately $240 million from institutional investors. The financing will close on or about March 9, 2026, and will be used to advance the company's pipeline of genetic medicines targeting neuromuscular and cardiac diseases. The placement was priced to meet Nasdaq's minimum price requirement.

Mar 6, 2026

▲ +20.3%on this news· ran to +43% by day 1shared move

Solid Biosciences Announces Oversubscribed 240 Million Private Placement

Mar 6, 2026

▲ +20.3%on this news· ran to +43% by day 1shared move

Solid Biosciences to Present at the 2026 Muscular Dystrophy Association MDA Clinical Scientific Conference

Mar 3, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 2, 2026

Solid Biosciences Inc. has announced the grant of 17,600 restricted stock units (RSUs) to a newly hired employee, as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employee's continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and underscores the company's commitment to attracting skilled professionals in the field of genetic medicine.

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences has received positive feedback from the FDA regarding the design of its Phase 3 trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The trial, named IMPACT DUCHENNE, is set to begin participant dosing in Q1 2026. The company is also planning further discussions with the FDA to explore an accelerated approval pathway. The ongoing Phase 1/2 trial has shown SGT-003 to be generally well tolerated among participants.

Feb 6, 2026

Solid Biosciences to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

Solid Biosciences Inc. will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026. CEO Bo Cumbo will discuss the company's advancements in precision genetic medicines targeting neuromuscular and cardiac diseases. The presentation will be available via live webcast and archived for 30 days.

Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101

Solid Biosciences has provided an optimistic outlook for 2026, highlighting progress in its neuromuscular and cardiac gene therapy pipelines. The company has initiated multiple clinical trials, including the Phase 1b FALCON trial for Friedreich's ataxia. Additionally, they have executed over 50 agreements for their next-generation capsid AAV-SLB101. CEO Bo Cumbo emphasized the commitment to advancing innovative therapies while addressing the needs of patients.

Jan 13, 2026

Solid Biosciences Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Solid Biosciences has received FDA Orphan Drug designation for SGT-212, a gene therapy aimed at treating Friedreich's ataxia. The company has completed dosing the first participant in the Phase 1b FALCON trial, with initial data expected in the second half of 2026. This therapy employs a dual-route administration to address the disease's neurological and cardiac manifestations.

Jan 12, 2026

Letter to the FA Community

Solid Biosciences has announced the dosing of the first participant in the FALCON trial, a Phase 1b study evaluating the safety and tolerability of SGT-212, a novel gene therapy for Friedreich's ataxia. The trial employs a dual-route administration strategy to address various manifestations of the disease. The company expresses gratitude to the FA community for their support and outlines plans for ongoing communication and updates as the study progresses.

Jan 12, 2026

Solid Biosciences Doses First Participant in First in Class Phase 1b FALCON Trial Evaluating SGT-212 Dual Route Gene Therapy for the Treatment of Friedreich s Ataxia

Jan 6, 2026

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - January 5, 2026

Solid Biosciences Inc. has announced the grant of 7,000 restricted stock units to a newly hired employee as part of its 2024 Inducement Stock Incentive Plan. This grant is in accordance with Nasdaq Listing Rule 5635(c)(4) and will vest over four years. The company focuses on developing genetic therapies for neuromuscular and cardiac diseases.

Jan 6, 2026

Solid Biosciences Present 44th Annual JP Morgan Healthcare

Jan 6, 2026

Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

Solid Biosciences Inc. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026. The company's President and CEO, Bo Cumbo, will provide insights into their ongoing efforts in developing precision genetic medicines for neuromuscular and cardiac diseases. Solid Biosciences boasts a range of gene therapy candidates, including those for Duchenne muscular dystrophy and other genetic cardiac diseases, signaling the company's commitment to innovation in this field.

Dec 16, 2025

Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U S Department of Health and Human Services

Dec 8, 2025

Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum

Solid Biosciences Inc. will present its proprietary AAV-SLB101 and cardiac gene therapy pipeline at the CVCT Forum in Washington, D.C. The company's Chief Medical Officer and Head of Discovery will share insights through presentations and panel discussions. This event emphasizes the importance of collaboration in advancing clinical trials and regulatory processes for cardiovascular treatments.

Dec 2, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 1, 2025

Solid Biosciences Inc. has announced the grant of 23,284 restricted stock units (RSUs) to two new employees as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employees' continued service. This move aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to enhance its workforce.

Dec 1, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Inc. has announced the grant of 23,284 restricted stock units (RSUs) to two newly hired employees as part of its 2024 Inducement Stock Incentive Plan. The RSUs will vest over four years, contingent on the employees' continued service. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and reflects the company's strategy to attract skilled professionals in the field of genetic medicine.

Dec 1, 2025

Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences has received FDA Rare Pediatric Disease designation for its gene therapy SGT-212, aimed at treating Friedreich's ataxia. This therapy uniquely utilizes dual routes of administration to deliver the frataxin gene. The company is also screening participants for its FALCON Phase 1b clinical trial. These designations may facilitate faster regulatory review and market access.

Nov 17, 2025

Solid Biosciences Announces Licensing Agreement with Andelyn Biosciences for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences has entered a non-exclusive licensing agreement with Andelyn Biosciences for its next-generation capsid, AAV-SLB101. This collaboration aims to enhance gene therapy development by integrating AAV-SLB101 into Andelyn's AAV Curator® Platform. The capsid has shown positive safety data in pediatric trials for Duchenne muscular dystrophy, with Solid pursuing broad licensing opportunities.

Nov 11, 2025

▲ +9.2%on this newsshared move

Solid Biosciences Participate Upcoming Investor Conferences

Nov 6, 2025

▲ +7.3%on this newsshared move

Solid Biosciences Awarded Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences has been awarded the Innovation Passport for SGT-003, a gene therapy for Duchenne muscular dystrophy, under the UK's Innovative Licensing and Access Pathway. This designation aims to accelerate the therapy's market entry and enhance patient access. SGT-003 is currently undergoing clinical trials in multiple countries, with the potential to transform treatment for Duchenne patients.

Nov 3, 2025

▼ -15.3%on this newsshared move

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions

Solid Biosciences reported positive interim results from its INSPIRE DUCHENNE trial for SGT-003, with 23 participants dosed and promising microdystrophin expression levels. The company plans to meet with the FDA in H1 2026 to discuss potential registrational pathways. Additionally, Solid has activated clinical trial sites for other programs targeting Friedreich's ataxia and catecholaminergic polymorphic ventricular tachycardia.

Oct 31, 2025

Solid Biosciences Reports Third Quarter 2025 Financial Results and Provides Update on INSPIRE DUCHENNE Clinical Trial Progress and Planned Regulatory Discussions - Duchenne (SGT-003): 23 participants have been dosed in t

Solid Biosciences has reported its Q3 2025 financial results and provided an update on the INSPIRE DUCHENNE trial, where 23 participants have been dosed with SGT-003. The treatment has shown encouraging safety and efficacy signals, including microdystrophin expression and early indicators of cardiac function normalization. The company aims to meet with the FDA in H1 2026 to discuss possible registrational pathways. Solid also plans to advance additional clinical trials for other candidates in its pipeline.

Oct 1, 2025

Solid Biosciences to Present at Upcoming Scientific Meetings

Solid Biosciences Inc. will present data from its neuromuscular and cardiac programs at the World Muscle Society and European Society of Gene & Cell Therapy annual congresses in October 2025. The presentations will showcase the potential of their innovative pipeline and proprietary capsid, AAV-SLB101. Following the conferences, the presentations will be accessible on their website.

Oct 1, 2025

Solid Biosciences Present Upcoming Scientific Meetings

Oct 1, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq

Solid Biosciences to Present at 2025 Neuromuscular Study Group Annual Scientific Meeting

Solid Biosciences will present data from the Phase 1/2 INSPIRE DUCHENNE trial for SGT-003 at the Neuromuscular Study Group Annual Meeting. The data includes updated safety information and previously reported biopsy results. The company highlights the favorable profile of SGT-003, particularly its liver tolerability and biomarker signals, while also discussing the potential of AAV-SLB101 in gene therapy.

Sep 25, 2025

▼ -5.1%on this newsshared move

Solid Biosciences Present 2025 Neuromuscular Study Group Annual

Sep 23, 2025

Solid Biosciences Announces Licensing Agreement with Kinea Bio for the Use of Proprietary Next-Generation Capsid AAV-SLB101

Solid Biosciences has entered a non-exclusive licensing agreement with Kinea Bio to utilize its proprietary capsid AAV-SLB101 for the development of KNA-155, a gene therapy targeting dysferlin-related limb-girdle muscular dystrophy. Solid will receive an upfront payment and potential royalties based on sales milestones. AAV-SLB101 has demonstrated enhanced muscle tropism and reduced liver biodistribution in preclinical studies.

Aug 12, 2025

Solid Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Updates

Solid Biosciences Receives FDA Fast Track Designation for SGT-501 First in Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia CPVT

Letter to the CPVT Community

Solid Biosciences has announced the initiation of a clinical trial for SGT-501, a gene therapy for CPVT caused by RYR2 mutations. Both the FDA and Health Canada have approved the applications to begin this important trial. The therapy aims to restore CASQ2 levels in heart muscle cells to stabilize heart rhythm. The company emphasizes its commitment to the CPVT community and patient engagement throughout the development process.

Jul 8, 2025

▲ +6.7%on this newsshared move

Solid Biosciences Announces FDA IND and Health Canada CTA Approval for First in Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia CPVT

May 28, 2025

▲ +7.2%on this news

Solid Biosciences to Participate at the Jefferies Global Healthcare Conference

Solid Biosciences Inc. will participate in the Jefferies Global Healthcare Conference on June 4, 2025, where President and CEO Bo Cumbo and Chief Medical Officer Gabriel Brooks will engage in a fireside chat. This event aims to showcase the company's efforts in developing precision genetic medicines targeting rare diseases. Additionally, institutional investors are invited to request meetings with the management during the conference for further discussions. Solid Biosciences emphasizes its patient-focused mission to improve the lives of patients suffering from serious conditions.

May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 30, 2025

▲ +8.5%on this news· ran to +39% by day 3shared move

Solid Biosciences to Participate at The Citizens Life Sciences Conference

Solid Biosciences Inc. will have its President and CEO, Bo Cumbo, participate in a fireside chat at The Citizens Life Sciences Conference on May 7, 2025. The event aims to provide insights into the company’s advancements in precision genetic medicines for neuromuscular and cardiac diseases. A live webcast of the discussion will be available, with a replay accessible for 30 days. Additionally, institutional investors are encouraged to connect with management during the conference.

Apr 29, 2025

▼ -5.6%on this news· ran to +33% by day 3shared move

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting

Solid Biosciences Inc. (Nasdaq: SLDB) will present data from the Phase 1/2 INSPIRE DUCHENNE trial evaluating SGT-003 at the upcoming ASGCT Annual Meeting. The company highlights significant advances in gene therapy for Duchenne muscular dystrophy, showcasing initial safety, expression, and biomarker data. Presentations will cover various aspects of their innovative therapy, emphasizing their commitment to develop effective genetic medicines for rare neuromuscular and cardiac conditions. The meeting will occur from May 13-17, 2025, in New Orleans, LA.

Mar 12, 2025

Solid Biosciences to Present at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

Solid Biosciences Inc. is set to present findings from its Phase 1/2 INSPIRE DUCHENNE trial at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference. The trial evaluates SGT-003, a next-generation gene therapy targeting Duchenne muscular dystrophy. This investigational gene therapy includes a unique microdystrophin construct and shows potential in addressing key symptoms of the disease. The event will take place in Dallas, TX from March 16-19, 2025.

Mar 12, 2025

Solid Biosciences Present 2025 Muscular Dystrophy Association

Mar 6, 2025

Solid Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Letter to the Duchenne Community – INSPIRE DUCHENNE Positive Initial Clinical Trial Data

Solid Biosciences has shared positive initial results from its Phase 1/2 INSPIRE DUCHENNE clinical trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The data shows promising microdystrophin expression and improvements in muscle health biomarkers among the first three patients. The therapy appears well-tolerated with no serious adverse events reported. The company plans to seek FDA guidance for accelerated approval in mid-2025.

Feb 18, 2025

▲ +31.5%on this newsshared move

Solid Biosciences Reports Positive Initial Clinical Data from Next Generation Duchenne Gene Therapy Candidate SGT-003

Feb 18, 2025

▲ +31.5%on this newsshared move

Solid Biosciences Announces Pricing of Underwritten Offering

Solid Biosciences Inc. has announced the pricing of an underwritten offering of approximately 35.7 million shares of its common stock at $4.03 per share, alongside pre-funded warrants for an expected total of $200 million in gross proceeds. The offering includes notable investors such as Adage Capital Partners and Bain Capital Life Sciences. The closing is anticipated on or about February 19, 2025, pending customary conditions. The company specializes in developing precision genetic medicines for neuromuscular and cardiac diseases.

Feb 11, 2025

February 2025 SGT-003 INSPIRE DUCHENNE DATA UPDATE 2025 Solid Biosciences Cautionary Note Regarding Forward Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Sec

Solid Biosciences provided an update on SGT-003 in the INSPIRE Duchenne trial, discussing advancements and ongoing clinical data as of February 2025. The presentation highlighted that six participants have been dosed with no serious adverse events reported. Promising results include localized nNOS activity in muscle fibers, but caution was advised regarding future expectations and potential risks in clinical and regulatory pathways. The company anticipates further updates as more participants are dosed throughout the year.

Jan 21, 2025

Solid Biosciences Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich s Ataxia

Jan 15, 2025

Solid Biosciences Outlines Key Priorities for Advancing Diversified Neuromuscular and Cardiac Development Pipeline and Establishing Leadership in Precision Genetic Medicines

Jan 8, 2025

Solid Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Inc. announced that its President and CEO, Bo Cumbo, will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. The company's focus is on developing precision genetic medicines to treat neuromuscular and cardiac diseases, with various gene therapy candidates in its pipeline. A live webcast of the presentation will be available, and there are opportunities for institutional investors to meet with the company's management during the event. Solid aims to improve the quality of life for patients affected by these diseases.

Jan 7, 2025

Solid Biosciences Announces FDA IND Clearance for First In Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich s At

Dec 23, 2024

Solid Biosciences Added to the Nasdaq Biotechnology Index

Dec 4, 2024

Solid Biosciences Announces Collaboration with Mayo Clinic to Accelerate Gene Therapy Innovation and Advance Development of Cardiac Gene Therapies

Nov 14, 2024

Solid Biosciences to Present at the Jefferies London Healthcare Conference

Solid Biosciences Inc. announced that its President and CEO, Bo Combo, along with Chief Medical Officer Gabriel Brooks, will present at the Jefferies London Healthcare Conference on November 20, 2024. The company, which specializes in precision genetic medicines for neuromuscular and cardiac diseases, is keen to engage with institutional investors during the event. A live webcast of the presentation will be available, along with a replay for 30 days. This conference marks an important opportunity for Solid Biosciences to showcase its advancements in gene therapy.

Letter to the Duchenne Community – INSPIRE DUCHENNE update & expansion

Solid Biociences provided an update on the INSPIRE DUCHENNE trial for SGT-003, a gene therapy for Duchenne muscular dystrophy. The Phase 1/2 study has dosed three participants with no serious adverse events, prompting an expansion of the trial to 43 participants. The age range for enrollment has also been broadened, and additional clinical sites will be activated.

Nov 6, 2024

Solid Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Updates

Oct 31, 2024

Solid Biosciences Participate Truist Securities Biopharma

Oct 31, 2024

Solid Biosciences to Participate at the Truist Securities BioPharma Symposium

Solid Biosciences Inc. announced that Dr. Gabriel Brooks, its Chief Medical Officer, will participate in the Genetic Medicine Panel at the Truist Securities BioPharma Symposium on November 7, 2024, in New York. This event presents an opportunity for the company to engage with institutional investors and discuss advancements in its pipeline, which includes gene therapy candidates for various cardiac and neuromuscular diseases. Solid's commitment to improving patient outcomes in these areas is evident in its diverse portfolio and mission-driven approach.

Sep 23, 2024

Solid Biosciences to Participate at Chardan’s 8th Annual Genetic Medicines Conference

Solid Biosciences Inc. (Nasdaq: SLDB) announced that its President and CEO Bo Cumbo, alongside Chief Medical Officer Gabriel Brooks, will participate in a fireside chat at Chardan's 8th Annual Genetic Medicines Conference on September 30, 2024. The conference will focus on advancements in genetic medicines for neuromuscular and cardiac diseases, showcasing the company's dedication to improving patient lives. A live webcast of the chat will be available, with a replay accessible for 30 days thereafter. The company has several gene therapy candidates and is actively engaged with institutional investors.

Sep 12, 2024

Solid Biosciences to Participate at the 2024 Cantor Global Healthcare Conference

Solid Biosciences Inc. will participate in the 2024 Cantor Global Healthcare Conference, highlighting its commitment to engaging with investors and stakeholders. Bo Cumbo, the President and CEO, along with Dr. Gabriel Brooks, the Chief Medical Officer, will be featured in a fireside chat. The event is scheduled for September 18, 2024, and will be accessible via live webcast, ensuring a broad audience reach. This participation underscores Solid's efforts to advance its gene therapy candidates for neuromuscular and cardiac diseases.

Aug 13, 2024

▲ +14.5%on this news· ran to +27% by day 3

Letter to the Duchenne Community – INSPIRE DUCHENNE update

Solid Biosciences has provided an update on its Phase 1/2 clinical trial, INSPIRE DUCHENNE, for SGT-003, a gene therapy for Duchenne muscular dystrophy. The trial has begun administering the therapy to patients, with no serious adverse events reported. The company plans to expand the trial to additional sites in North America and Europe, aiming to enhance patient participation and transparency.

Aug 13, 2024

Solid Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Updates

Aug 5, 2024

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Solid Biosciences Inc. has granted 86,665 restricted stock units (RSUs) to four newly hired employees as part of its 2024 Inducement Stock Incentive Plan, following Nasdaq Listing Rule 5635(c)(4). One employee also received an option to buy 100,000 shares of common stock, vesting over four years. These grants aim to enhance the company's ability to attract and retain talent while advancing its pipeline of genetic therapies for serious diseases, including Duchenne muscular dystrophy and cardiac conditions.

Solid Biosciences Joins the Russell 3000 Index

Solid Biosciences Reports Inducement Grant Under Nasdaq Listing

May 15, 2024

Solid Biosciences Provides First Quarter 2024 Business Update and Financial Results

May 7, 2024

Solid Biosciences Present American Society Gene And Cell

May 7, 2024

Solid Biosciences to Present at the American Society of Gene and Cell Therapy Annual Meeting

Solid Biosciences Inc. is set to present its advancements in gene therapy at the upcoming American Society of Gene and Cell Therapy Annual Meeting. The presentations will showcase improvements in AAV manufacturing, purification methods, and updates on the lead SGT-003 program, focusing on its potential in treating Duchenne muscular dystrophy. CEO Bo Cumbo expressed enthusiasm about sharing the company's scientific findings and innovations. These developments indicate Solid's commitment to addressing unmet medical needs in neuromuscular and cardiac diseases.

Apr 1, 2024

▼ -6.6%on this newsshared move

Solid Biosciences Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Mar 27, 2024

▲ +5%on this newsshared move

Solid Biosciences Participate Cantors Virtual Muscular Dystrophy

Mar 27, 2024

▲ +5%on this newsshared move

Solid Biosciences to Participate at Cantor’s Virtual Muscular Dystrophy Symposium

Solid Biosciences Inc. has announced that its President and CEO Bo Cumbo, alongside CMO Gabriel Brooks, will present at the upcoming Cantor's Virtual Muscular Dystrophy Symposium set for April 2, 2024. The company aims to highlight its advancements in gene therapy candidates targeting rare neuromuscular and cardiac diseases. This presentation underscores Solid Biosciences' commitment to improving the lives of patients affected by such conditions through innovative treatments.

Solid Biosciences Provides Fourth Quarter And Full Year 2023

Mar 7, 2024

▲ +7.9%on this news· ran to +21% by day 3

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV SLB101 a Proprietary Muscle Targeted Capsid in the Development of an RNAi Therapy to treat FSHD

Jan 16, 2024

Solid Biosciences Granted FDA Orphan Drug Designation Duchenne

Jan 8, 2024

▲ +7.6%on this news· ran to +46% by day 1

Solid Biosciences Announces 109 Million Private Placement

Jan 8, 2024

▲ +7.6%on this news· ran to +46% by day 1

Forward Looking Statement This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding future expectations, plans and

Solid Biosciences presented forward-looking statements regarding its future expectations at the 42nd Annual J.P. Morgan Healthcare Conference in January 2024. The company discussed its advancement in clinical trials for its product candidates SGT-003 and SGT-501, with expected milestones and potential benefits, particularly for Duchenne Muscular Dystrophy. However, various risks and uncertainties were highlighted, including regulatory approvals and competition within the biopharma sector.

Jan 4, 2024

Solid Biosciences to Participate at 42nd Annual J.P. Morgan Healthcare Conference

Solid Biosciences Inc. announced that its CEO, Bo Cumbo, will present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024. The company focuses on developing precision genetic medicines for various neuromuscular and cardiac diseases, featuring multiple gene therapy candidates. The conference will provide an opportunity for institutional investors to engage with company management. A live webcast of the presentation will also be available for broader audience access.

Solid Biosciences Receives FDA Fast Track Designation for Duchenne Muscular Dystrophy Gene Therapy SGT-003

Solid Biosciences has announced that its Duchenne muscular dystrophy gene therapy candidate, SGT-003, has received Fast Track Designation from the FDA. This designation aims to facilitate its expedited development due to the high unmet needs in the Duchenne community. Following the recent IND clearance for SGT-003, a Phase 1/2 trial will begin to assess its safety and tolerability in pediatric patients. The company emphasizes its commitment to developing a potentially life-changing therapy while collaborating closely with the FDA throughout the process.

Solid Biosciences Participate 35th Annual Piper Sandler

Nov 22, 2023

▲ +9.2%on this news

Solid Biosciences to Participate at 35th Annual Piper Sandler Healthcare Conference

Solid Biosciences Inc. announced that its CEO, Bo Cumbo, will present at the 35th Annual Piper Sandler Healthcare Conference on November 30, 2023. The company specializes in precision genetic medicines for neuromuscular and cardiac diseases. Interested institutional investors can schedule meetings with the management team during the conference. Solid Biosciences is focused on advancing a pipeline of gene therapy candidates aimed at treating serious conditions such as Duchenne muscular dystrophy and various cardiac diseases.

Nov 14, 2023

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Solid Biosciences has received FDA clearance for its investigational new drug application for SGT-003, a gene therapy candidate targeting Duchenne muscular dystrophy. The company plans to initiate a Phase 1/2 trial focusing on pediatric patients aged 4 to under 6 years. SGT-003 utilizes a differentiated delivery method that aims for improved safety and efficacy in treatment. The initiative is considered a significant step toward addressing the pressing needs within the Duchenne community.

Nov 9, 2023

▼ -23.7%on this newsshared move

Solid Biosciences Participate Jefferies London Healthcare

Nov 9, 2023

▼ -23.7%on this newsshared move

Solid Biosciences to Participate at Jefferies London Healthcare Conference

Solid Biosciences Inc. will present at the Jefferies London Healthcare Conference on November 15, 2023, at 5:00 pm GMT. CEO Bo Cumbo will represent the company, showcasing its focus on precision genetic medicines for neuromuscular and cardiac diseases. Investors interested in dialogue with management are encouraged to contact their Jefferies representatives. Solid's ongoing efforts include the development of therapies for conditions like Duchenne muscular dystrophy and catecholaminergic polymorphic ventricular tachycardia.

Nov 8, 2023

Solid Biosciences to Participate in Citi’s 18th Annual BioPharma Conference

Solid Biosciences Inc. has announced its participation in the Citi 18th Annual BioPharma Conference, scheduled for September 7, 2023. Bo Cumbo, the company’s CEO, will present at the event. A live webcast of the presentation will be available for investors, and a replay will be accessible for 30 days post-event. Solid Biosciences is focused on creating genetic therapies for neuromuscular and cardiac diseases, including several promising programs.

Aug 31, 2023

Solid Biosciences Participate Citis 18th Annual Biopharma

Aug 14, 2023

Solid Biosciences Provides Second Quarter Business Update and Financial Results

Jun 1, 2023

Solid Biosciences to Participate at the Jefferies Healthcare Conference

Solid Biosciences Inc. announced its participation in the Jefferies Healthcare Conference on June 8, 2023, where CEO Bo Cumbo will host a fireside chat. An online webcast of the discussion will be available for interested parties. The company, focused on developing genetic medicines for neuromuscular and cardiac diseases, aims to connect with institutional investors at the event.

Jun 1, 2023

Solid Biosciences Participate Jefferies Healthcare Conference

May 22, 2023

Solid Biosciences to Participate at the Barclays Gene Editing & Therapy Summit

Solid Biosciences Inc. announced that Bo Cumbo, its CEO, will participate in a fireside chat at the Barclays Gene Editing & Therapy Summit on May 24, 2023. This event provides an opportunity for investors to gain insights into the company’s direction in developing genetic medicines for neuromuscular and cardiac diseases. The company will also make a live webcast of the chat available for interested parties. Solid is focused on advancing treatments for conditions such as Duchenne muscular dystrophy and Friedreich's Ataxia.

May 16, 2023

Solid Biosciences Present American Society Gene And Cell Therapy

May 11, 2023

Solid Biosciences Provides First Quarter Business Update And

May 8, 2023

Solid Biosciences to Present at JMP Securities Life Sciences Conference

Solid Biosciences Inc. announced that its CEO, Bo Cumbo, will present at the JMP Securities Life Sciences Conference on May 15, 2023. This appearance will introduce their ongoing projects, particularly in the fields of neuromuscular and cardiac diseases. A live webcast of the presentation will be available, as well as a recorded replay for later access. The company aims to improve the lives of patients suffering from Duchenne and other conditions through innovative genetic therapies.

May 8, 2023

Solid Biosciences Present Jmp Securities Life Sciences

Apr 21, 2023

Solid Biosciences to Participate in Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

Solid Biosciences Inc. will take part in Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on April 24, 2023. The event will feature a fireside chat with company management, aimed at discussing advancements in genetic medicines. A live webcast of the discussion will be accessible on the Company's website, allowing broader participation. The company continues to focus on developing treatments for neuromuscular and cardiac diseases.

Apr 21, 2023

Solid Biosciences Participate Chardans 7th Annual Genetic

Apr 13, 2023

Solid Biosciences to Present at the 22nd Annual Needham Healthcare Conference

Solid Biosciences Inc. will present at the 22nd Annual Needham Healthcare Conference on April 20, 2023. CEO Bo Cumbo is set to present at 8:00 AM ET, followed by a gene therapy panel discussion later that day. A live webcast of the presentation will be available, enhancing transparency for investors. This participation highlights the company's commitment to advancing genetic medicines for neuromuscular and cardiac diseases.

Apr 13, 2023

Solid Biosciences Present 22nd Annual Needham Healthcare

Mar 23, 2023

Solid Biosciences Provides Fourth Quarter And Full Year 2022

Mar 21, 2023

Solid Biosciences Participate Bmo Biopharma Spotlight Series

Mar 21, 2023

Solid Biosciences to Participate at BMO Biopharma Spotlight Series: Genetic Medicine Delivery

Solid Biosciences Inc. announced the participation of its CEO, Bo Cumbo, in the BMO Biopharma Spotlight Series focusing on genetic medicine delivery. He will discuss innovative AAVs targeting diverse tissues in a panel set for March 28, 2023. The event will be exclusive to BMO clients, with a replay also available on the company's website. Solid Biosciences is committed to developing therapies for neuromuscular and cardiac diseases.

Mar 20, 2023

▼ -10.5%on this newsshared move

SOLID BIO SCIENCES IGNITE DMD Phase I/II Study of SGT-001 Microdystrophin Gene Therapy for Duchenne Muscular Dystrophy Roxana Donisa Dreghici1, J. Patrick Gonzalez1, Kristy J. Brown1, Carl A. Morris1, Perry Shieh2, Barry

The Phase I/II IGNITE DMD study by Solid Biosciences is assessing the gene therapy SGT-001 for Duchenne Muscular Dystrophy (DMD). Results show positive changes in motor and pulmonary function at the one-year mark, with all subjects completing this time point and no new treatment-associated adverse events noted after the initial 90 days. Despite some serious adverse events reported, the study indicates promising outcomes for further trials. Solid Biosciences is also moving forward with the next-generation SGT-003 program, which is currently in IND-enabling studies.

Mar 7, 2023

▲ +5%on this news

Solid Biosciences to Present at Barclays Global Healthcare Conference

Feb 8, 2023

▼ -5.7%on this news

Solid Biosciences Present Svb Securities Global Biopharma

Feb 8, 2023

▼ -5.7%on this news

Solid Biosciences to Present at SVB Securities Global Biopharma Conference

Solid Biosciences Inc. announced that CEO Bo Cumbo will present at the SVB Securities Global Biopharma Conference on February 15, 2023. The event aims to showcase the company's advancements in genetic medicines for neuromuscular and cardiac diseases. Investors can access a live webcast of the presentation and request meetings with the management team during the conference. Solid's commitment to developing treatments for debilitating conditions could attract further interest from institutional investors.

Solid Tumor Testing Market Worth USD 59.45 Bn by 2029 Recent trends, mergers and acquisitions, region-wise growth analysis along with challenges

The Solid Tumor Testing Market is projected to experience significant growth, expanding from USD 32.48 billion in 2021 to USD 59.45 billion by 2029, reflecting a CAGR of 7.85%. This growth is attributed to technological advancements, an increase in cancer cases, and the rising demand for improved diagnostic testing methodologies such as next-generation sequencing and immunohistochemistry. Major players are leveraging strategies like acquisitions and partnerships to enhance their market positions. The North American market is anticipated to dominate during the forecast period due to its advanced healthcare infrastructure and research capabilities.

Jan 11, 2023

▲ +5%on this news· ran to +20% by day 3shared move

Solid Biosciences and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Jan 10, 2023

Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases

Solid Biosciences has outlined its strategic priorities for 2023, focusing on advancing its pipeline of genetic medicines for neuromuscular and cardiac diseases. Key highlights include the expected IND application for SGT-003 for Duchenne muscular dystrophy and ongoing development of AVB-202 for Friedreich's Ataxia. The company enters 2023 with significant financial resources, which are projected to support its goals into 2025. Additionally, the appointment of Kevin Tan as Chief Financial Officer aims to bolster execution of their corporate strategy.

Jan 10, 2023

Solid Biosciences Outlines Strategy Leadership Precision Genetic

Solid Biosciences Appoints Kevin Tan CFA Chief Financial Officer

Solid Biosciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Solid Biosciences Inc. will present at the 41st Annual J.P. Morgan Healthcare Conference on January 12, 2023. Bo Cumbo, the company's CEO, will represent Solid, providing insights into their genetic medicines for neuromuscular and cardiac diseases. The event underscores the company's commitment to advancing their innovative programs aimed at improving patient lives.

Solid Biosciences Appoints Kevin Tan, CFA, as Chief Financial Officer

Solid Biosciences Inc. has appointed Kevin Tan as Chief Financial Officer, bringing over 20 years of experience in the biopharmaceutical industry. His prior roles include CFO at Selecta Biosciences and Treasurer at Sarepta Therapeutics, where he developed strong financial and strategic skills. Tan expressed excitement about joining the management team and indicated confidence in the company's financial position to drive value in the future.

Solid Biosciences Reports Inducement Grant to Chief Financial Officer and Treasurer

Solid Biosciences Inc. has announced an inducement grant to its newly appointed Chief Financial Officer and Treasurer, Kevin Tan. The inducement includes an option to purchase 90,000 shares of common stock and a restricted stock unit award of 45,000 shares. The grants aim to support Mr. Tan's transition into the role, with a vesting schedule that encourages long-term commitment to the company. This move reflects Solid Biosciences' strategy to strengthen its leadership team as it continues to develop genetic medicines for neuromuscular and cardiac diseases.

Solid Biosciences Present 41st Annual JP Morgan Healthcare

Dec 5, 2022

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing

Dec 5, 2022

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led

Solid Biosciences Announces Closing of Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions create a precision genetic medicine company focused on neuromuscular and cardiac diseases, led by industry veteran Bo Cumbo - - Company to leverage syner

Dec 1, 2022

SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this Amended and Restated 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Com

SOLID BIOSCIENCES INC. AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN The purpose of this Amended and Restated 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by

Dec 1, 2022

Solid Biosciences Announces Stockholder Approval of Acquisition of AavantiBio

- Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases - CHARLESTOWN, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for D

Dec 1, 2022

Solid Biosciences Announces Stockholder Approval Acquisition

Nov 22, 2022

Solid Biosciences to Participate at the Piper Sandler 34th Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Foun

Nov 22, 2022

Solid Biosciences Participate Piper Sandler 34th Annual

Nov 10, 2022

Solid Biosciences Provides Third Quarter 2022 Business Update and Financial Results

Oct 27, 2022

Solid Biosciences Announces a 1 for 15 Reverse Stock Split

Oct 17, 2022

Solid Biosciences Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle

- AAV-SLB101 is the capsid used in SGT-003, Solid’s next-generation Duchenne gene therapy, expected to enter the clinic in late-2023 - - Additional novel capsids based on AAV-SLB101 binding protein data are also under evaluation and offer potential to improve safety and efficacy

Oct 13, 2022

Solid Biosciences Presents New SGT-001 IGNITE DMD Study Results at World Muscle Society 2022 Congress Demonstrating Improvements in Ambulatory Function

Sep 30, 2022

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by

Solid Biosciences Announces Acquisition of AavantiBio and Concurrent $75 Million Private Placement - Transactions to create a precision genetic medicine company focused on neuromuscular and cardiac rare diseases, led by industry veteran and current AavantiBio CEO, Bo Cumbo - -

Sep 30, 2022

Solid Biosciences Business Update Call

Business Update Call Caitlin Lowie - VP, Communications and IR, Solid Biosciences Ilan Ganot - Co-Founder, President and CEO, Solid Biosciences Bo Cumbo - President, Chief Executive Officer of AavantiBio Carl Morris - Chief Financial Officer, Solid Biosciences Jenny Marlow -

Aug 11, 2022

Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results - Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients i

Solid Biosciences Provides Second Quarter 2022 Business Update and Financial Results - Transition to transient transfection-based manufacturing process continues for SGT-001; Company expects to continue dosing patients in 2023 - - Development of next-generation Duchenne gene t

Jun 23, 2022

▲ +8.5%on this news

Solid Biosciences Present Upcoming Scientific And Patient

Jun 23, 2022

▲ +8.5%on this news

Solid Biosciences to Present at Upcoming Scientific and Patient Advocacy Conferences

CAMBRIDGE, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming sci

Jun 2, 2022

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Quality

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vi

Jun 2, 2022

Solid Biosciences Reports Inducement Grant New Senior Vice

May 17, 2022

Solid Biosciences to Present at ASGCT 25th Annual Meeting and CureDuchenne 2022 FUTURES National Conference

CAMBRIDGE, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate in the following upcoming scie

Apr 27, 2022

▼ -17%on this news· ran to -29% by day 3

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy - IGNITE DMD functional and durability patient data support advancemen

Solid Biosciences Announces Updated Corporate Strategy to Develop SGT-001 and SGT-003 Pipeline Programs for Patients with Duchenne Muscular Dystrophy - IGNITE DMD functional and durability patient data support advancement of SGT-001; Program transitioning to a commercially scal

Apr 27, 2022

▼ -17%on this news· ran to -29% by day 3

Solid Biosciences Management Host Call April 27 2022 Discuss

Apr 25, 2022

Solid Biosciences Management to Host Call on April 27, 2022 to Discuss Updated Corporate Strategy and First Quarter 2022 Financial Results

CAMBRIDGE, Mass., April 25, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2022 financial results befo

Mar 14, 2022

▼ -6.1%on this news· ran to +22% by day 3

Solid Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and 2 Year Efficacy and Safety Data from the Ongoing Phase I II IGNITE DMD Clinical Trial of SGT-001

Feb 10, 2022

▼ -6.5%on this news

Solid Biosciences to Participate at the SVB Leerink 11th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, and Carl Mor

Solid Biosciences Participate Svb Leerink 11th Annual Global

Jan 10, 2022

Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy pro

Solid Biosciences Outlines its Strategic Priorities for 2022 and Announces Corporate Updates - Continue to advance SGT-001 by dosing additional patients in IGNITE DMD - - Advance next-generation Duchenne gene therapy program (SGT-003) to IND submission; SGT-003 has demonstrated

Jan 6, 2022

Solid Biosciences Present 40th Annual JP Morgan Healthcare

Jan 6, 2022

Solid Biosciences to Present at 40th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Foun

Jan 4, 2022

Solid Biosciences Reports Inducement Grant to New Senior Vice President Human Resources

Solid Biosciences Provides Third Quarter 2021 Business Update and Financial Results

Oct 21, 2021

Solid Biosciences Participate Jefferies Gene Therapyediting

Oct 21, 2021

Solid Biosciences to Participate at the Jefferies Gene Therapy/Editing Summit

CAMBRIDGE, Mass., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Co-Founder, President and Chief Executive Offi

Oct 4, 2021

Solid Biosciences And Forge Biologics Announce Viral Vector

Sep 29, 2021

Solid Biosciences Reports Additional Pulmonary Function Results from the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Improvements in two additional assessments of pulmonary function in treated patients compared with untreated control patients further support potential functional benefit of SGT-001 one-year post administration - - Data presented at the Child Neurology Society 50th Annual Meet

Sep 23, 2021

Solid Biosciences Reports 1.5-Year Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) - - Patient reported outcomes showed sustained improvements at

Sep 20, 2021

▼ -5%on this newsshared move

Solid Biosciences Provide Update Long Term Outcomes Data

Sep 20, 2021

▼ -5%on this newsshared move

Solid Biosciences to Provide Update on Long-Term Outcomes Data from Patients in the Ongoing IGNITE DMD Phase I/II Clinical Trial of SGT-001

- Functional and patient-reported outcomes data for the first three patients in the high-dose (2E14 vg/kg) cohort (Patients 4-6) 1.5 years post-dosing to be presented at the World Muscle Society 2021 Virtual Congress - CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Solid B

Aug 24, 2021

Solid Biosciences to Present at the 11th Annual World Orphan Drug Congress USA 2021

- Chief Operating Officer to discuss company’s advanced AAV gene therapy manufacturing capabilities and best practices for orphan drug development - CAMBRIDGE, Mass., Aug. 24, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on adva

Aug 19, 2021

▼ -6.2%on this newsshared move

Solid Biosciences Announces Appointment Michael Inbar CPA MBA

Aug 19, 2021

▼ -6.2%on this newsshared move

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Finance

CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of inducement awards to its newly appointed Senior Vi

Aug 19, 2021

▼ -6.2%on this newsshared move

Solid Biosciences Announces Appointment of Michael Inbar, CPA, MBA, as Senior Vice President, Finance

CAMBRIDGE, Mass., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Michael Inbar, CPA, MBA, has joined the Company as Senior

Aug 16, 2021

▼ -5.6%on this newsshared move

Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results - Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development acti

Solid Biosciences Provides Second Quarter 2021 Business Update and Financial Results - Clinical activities underway to advance patient dosing in IGNITE DMD; next patient dosing anticipated in Q4 2021 - - Development activities continue for pipeline initiatives SGT-003 and Ultra

Jul 2, 2021

Solid Biosciences Reports Inducement Grant to New Senior Vice President, Clinical Development

CAMBRIDGE, Mass., July 02, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Senior

Jul 1, 2021

Solid Biosciences Strengthens Management Team to Advance Programs for Duchenne Muscular Dystrophy

Jun 17, 2021

The 2020 Stock Incentive Plan (the Plan ) of Solid Biosciences Inc.

2020 STOCK INCENTIVE PLAN The 2020 Stock Incentive Plan (the Plan ) of Solid Biosciences Inc. is hereby amended as follows: 1. Section 4(a)(1)(A) of the Plan is hereby deleted and a new Section 4(a)(1)(A) is inserted in lieu thereof which shall read as (A) 10,000,000 shares of

Jun 7, 2021

Solid Biosciences Announces Appointment Iman Barilero Pharmd Phd

Jun 7, 2021

Solid Biosciences Reports Inducement Grant to New Chief Regulatory Officer

Jun 7, 2021

Solid Biosciences Announces Appointment of Iman Barilero, PharmD, Ph.D., as Chief Regulatory Officer

CAMBRIDGE, Mass., June 07, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Dr. Iman Barilero has joined the Company as Chief Regulato

May 26, 2021

Solid Biosciences Present Jefferies Virtual Healthcare

May 26, 2021

Solid Biosciences to Present at the Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 26, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Operating Officer, will present

May 25, 2021

Solid Biosciences to Present at Upcoming Scientific Conferences

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that the Company will participate at the following upcoming scie

May 25, 2021

Solid Biosciences Present Upcoming Scientific Conferences

May 14, 2021

Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results - Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing

Solid Biosciences Provides First Quarter 2021 Business Update and Financial Results - Patients 7 and 8 dosed in IGNITE-DMD Phase I/II clinical trial under new clinical protocol and second-generation SGT-001 manufacturing process; patient 8 experienced a serious adverse event -

May 14, 2021

Solid Biosciences Host First Quarter 2021 Financial Results And

May 11, 2021

Solid Biosciences to Host First Quarter 2021 Financial Results and Business Update Call on May 14, 2021

CAMBRIDGE, Mass., May 11, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release first quarter 2021 financial results before

May 4, 2021

Solid Biosciences Highlights Expertise in AAV Gene Therapy with Multiple Abstracts to be Presented at the American Society of Gene & Cell Therapy 24th Annual Meeting

-Data from studies of novel AAV vectors and AAV immunology and an encore of 12-month safety, efficacy and patient-reported outcomes measurements from the ongoing IGNITE DMD trial of SGT001 to be presented- CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc.

May 4, 2021

Solid Biosciences Highlights Expertise AAV Gene Therapy Multiple

Apr 20, 2021

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 5th Annual Genetic Medicines Manufacturing Summit

CAMBRIDGE, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, Ph.D., Chief Operating Officer, and Louis

Apr 20, 2021

Solid Biosciences Participate Virtual Fireside Chat Chardan 5th

Mar 25, 2021

Solid Biosciences to Participate at Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Day

CAMBRIDGE, Mass., March 25, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Carl Morris, Ph.D., Chief Scientific Officer, will partic

Mar 25, 2021

Solid Biosciences Participate Guggenheim Healthcare Talks

Mar 23, 2021

Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over Allotment Option

Mar 18, 2021

Solid Biosciences Announces Pricing Public Offering Common Stock

Mar 18, 2021

Solid Biosciences Announces Pricing of Public Offering of Common Stock

Solid Biosciences Announces Pricing of Public Offering of Common Stock CAMBRIDGE, Massachusetts, March 18, 2021 Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced t

Mar 17, 2021

Solid Biosciences Announces Proposed Public Offering of Common Stock

Mar 15, 2021

Solid Biosciences Reports Positive Interim Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort - Interim data from six patients provide evidence o

Solid Biosciences Reports Positive Interim Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort - Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints

Mar 15, 2021

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg kg Cohort

Mar 4, 2021

Solid Biosciences Reports Inducement Grant to New Chief Legal Officer

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief

Mar 4, 2021

Solid Biosciences Announces Appointments to Management Team and Board of Directors

Feb 24, 2021

Efficacy and Safety Data from Solid Biosciences Ongoing IGNITE DMD Phase I II Clinical Trial to be Presented at the 2021 MDA Clinical Scientific Conference

Feb 17, 2021

Solid Biosciences Present Upcoming Investor Conferences

Feb 17, 2021

Solid Biosciences to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn

Jan 6, 2021

Solid Biosciences Present 39th Annual JP Morgan Healthcare

Jan 6, 2021

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Foun

Dec 11, 2020

Solid Biosciences Announces $90 Million Private Placement Cambridge, MA

Solid Biosciences Announces $90 Million Private Placement Cambridge, MA December 11, 2020 - Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered i

Nov 5, 2020

Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 -Collaboration with Ultragenyx creates opportun

Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 -Collaboration with Ultragenyx creates opportunities to develop additional gene therapies for Duchene mus

Nov 5, 2020

Solid Biosciences Host Third Quarter 2020 Financial Results And

Nov 3, 2020

Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release third quarter 2020 financial results befor

Oct 2, 2020

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneid

Oct 2, 2020

Solid Biosciences Participate Virtual Fireside Chat Chardan 4th

Oct 1, 2020

Solid Biosciences Announces FDA Lifts Clinical Hold on IGNITE DMD Clinical Trial

Jul 24, 2020

Solid Biosciences Provides Update Regarding the IGNITE DMD Phase I II Clinical Hold

Jun 18, 2020

Solid Biosciences Announces Appointment Ian F Smith Chairman

Jun 18, 2020

SOLID BIOSCIENCES INC. 2020 EQUITY INCENTIVE PLAN 1. Purpose The purpose of this 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Company ), is to advance the interests of the

SOLID BIOSCIENCES INC. EQUITY INCENTIVE PLAN The purpose of this 2020 Equity Incentive Plan (the Plan ) of Solid Biosciences Inc., a Delaware corporation (the Company ), is to advance the interests of the Company s stockholders by enhancing the Company s ability to attract, re

Jun 18, 2020

Solid Biosciences Announces Appointment of Ian F. Smith as Chairman of the Board of Directors

CAMBRIDGE, Mass., June 18, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy, announced today the appointment of board member Ian F. Smith as Chairman of the Board. Mr.

Jun 16, 2020

Solid Biosciences Hold Virtual Annual Meeting Stockholders June

May 22, 2020

Solid Biosciences to Hold Virtual Annual Meeting of Stockholders on June 16 2020

May 14, 2020

Solid Biosciences Presents Data from Duchenne Muscular Dystrophy Gene Therapy Program at ASGCT 23rd Annual Meeting

Virtual oral presentation reviews interim clinical biomarker data for SGT-001 and provides data on expression and co-localization of microdystrophin and dystrophin associated proteins in patients in the IGNITE DMD trial Virtual poster presentation provides data characterizing no

May 14, 2020

Solid Biosciences Presents Data Duchenne Muscular Dystrophy Gene

May 7, 2020

Solid Biosciences Provides Update regarding SGT-001 Phase I II Clinical Hold on IGNITE DMD

Apr 16, 2020

Solid Biosciences Announces Appointment of Ian F Smith to its Board of Directors

Mar 12, 2020

Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provides furth

Solid Biosciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update Biopsy results from the third patient dosed at 2E14 vg/kg in the SGT-001 IGNITE DMD clinical trial provides further support for continued development Solid continues to

Jan 9, 2020

Solid Biosciences Announces Organizational Changes to Prioritize Development of SGT-001

Dec 18, 2019

Solid Biosciences Provides Data Update from SGT-001 Development Program

Nov 12, 2019

Solid Biosciences Provides SGT-001 Program Update

Oct 2, 2019

Solid Biosciences to Participate in the Chardan 3rd Annual Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced that Joel Schneider, PhD., Chief Technology Officer, will participate in a webcast question and answer session at the upcoming Chardan Annual Genetic Medicines Conference at

Oct 2, 2019

Solid Biosciences Participate Chardan 3rd Annual Genetic

Sep 5, 2019

Solid Biosciences Announces Publication Highlighting Important

Aug 14, 2019

Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial Study protocol amended to expedite clinical executi

Solid Biosciences Reports Second Quarter 2019 Financial Results and Provides Business Update Additional patient dosed at 2E14 vg/kg in second cohort of IGNITE DMD trial Study protocol amended to expedite clinical execution of SGT-001 Recent $60M capital raise extends runway in

Jul 26, 2019

Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors Cambridge, MA

Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors Cambridge, MA July 26, 2019 Solid Biosciences Inc. (Nasdaq: SLDB) today announced that it has entered into a securities purchase agreement with a select group of institutional investors an

May 13, 2019

Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg Clinical activities unde

Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update Dosing of SGT-001 initiated in second cohort of patients in the IGNITE DMD clinical trial at Clinical activities underway at additional study sites Cambridge, MA May 13, 2019 Solid Bios

Apr 15, 2019

Solid Biosciences Announces Upcoming Preclinical Data Presentations at The American Society of Gene and Cell Therapy Annual Meeting

Mar 13, 2019

Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg

Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update Activities underway to commence dosing of second cohort of patients in the IGNITE DMD clinical trial at 2E14 vg/kg of SGT-001 Cambridge, MA March 13, 2019 - Solid Biosci

Feb 7, 2019

Solid Biosciences Announces Preliminary SGT-001 Data and Intention to Dose Escalate in IGNITE DMD Clinical Trial for Duchenne Muscular Dystrophy

Jan 8, 2019

Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties. These forw

Solid Biosciences Ilan Ganot, Co-Founder, CEO and President January 2019 Exhibit 99.1 Forward-Looking Statements This presentation includes "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, which involve a number of risks

Jan 2, 2019

Solid Biosciences Present JP Morgan Healthcare Conference

Jan 2, 2019

Solid Biosciences to Present at the J.P. Morgan Healthcare Conference

CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Ilan Ganot, Co-Founder, Chief Executive Officer and President of Solid Biosciences will present at the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Januar

Nov 13, 2018

Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Result

Solid Biosciences Reports Third Quarter 2018 Financial Results And Provides Business Update Two Additional Patients Dosed With SGT-001 Gene Transfer in IGNITE DMD Clinical Trial Company Plans to Report Preliminary Results from IGNITE DMD in the First Quarter of 2019 Cambridge

Nov 9, 2018

Solid Biosciences to Present at the Credit Suisse Healthcare Conference

CAMBRIDGE, Mass., Nov. 09, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Credit Suisse 27th Annual Healthcare Conference on Wednesday, November 14, 2018 at 2:50 pm MT in Scottsdale, Arizona. The Credit Suisse H

Oct 5, 2018

Solid Biosciences to Present at the Chardan Genetic Medicines Conference

CAMBRIDGE, Mass., Oct. 05, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will participate in a question and answer format presentation at the Chardan Capital Markets 2nd Annual Genetic Medicines Conference on Tuesday, October 9, 20

Oct 1, 2018

Solid Biosciences to Present at the Cell & Gene Meeting on the Mesa

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that management will present at the Cell & Gene Meeting on the Mesa on Wednesday, October 3, 2018 at 3:30 pm PT in La Jolla, California. The Cell & Gene Meeting on the Mesa

Sep 13, 2018

Solid Biosciences Welcomes Sukumar Nagendran, M.D., To Its Board Of Directors

CAMBRIDGE, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ: SLDB) today announced that Sukumar Nagendran, M.D., has been elected to its Board of Directors. Dr. Nagendran brings to Solid more than 30 years of experience in key functional areas, including g

Aug 10, 2018

Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update - IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed - Cambridge, MA

Solid Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update - IGNITE DMD Phase I/II Clinical Trial Patient Screening Has Resumed - Cambridge, MA August 10, 2018 - Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the seco

Jun 26, 2018

Solid Biosciences Welcomes Industry Expert Dr. Martin Freed To Its Board Of Directors

Ilan Ganot, Co-Founder and CEO, Assumes Additional Role of President Gilad Hayeem, Co-Founder, President and Board Member, Retires to Pursue Other Activities CAMBRIDGE, Mass., June 26, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that Martin Fre

Jun 18, 2018

Solid Biosciences Announces FDA Removes Clinical Hold SGT-001

May 19, 2018

SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB

NEW ORLEANS, May 18, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (Nasdaq:SLDB), if they pu

May 18, 2018

Solid Biosciences Announces New Preclinical Data at the American Society of Gene and Cell Therapy Annual Meeting

May 15, 2018

Solid Biosciences Announces Upcoming Preclinical Data Presentations

CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) today announced that new preclinical data from its Duchenne muscular dystrophy (DMD) programs, including its lead gene transfer candidate, SGT-001, will be presented at the 21st Annual Meeting

May 12, 2018

SOLID BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB

NEW ORLEANS, May 11, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit ag

May 10, 2018

Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update - Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial - Cambridge, MA

Solid Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update - Company Finalizing Response to FDA Regarding Clinical Hold on SGT-001 Phase I/II Clinical Trial - Cambridge, MA - May 10, 2018 - Solid Biosciences Inc. (NASDAQ:SLDB) today reported fi

Apr 18, 2018

Solid Biosciences Provides Update On SGT-001 Clinical Development Program For Duchenne Muscular Dystrophy

Apr 14, 2018

SOLID BIOSCIENCES SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB

NEW ORLEANS, April 13, 2018 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (NasdaqGS:SLDB), if the

Mar 29, 2018

Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update - Company Continues To Work To Address Clinical Hold On IGNITE DMD - Cambridge, MA

Solid Biosciences Reports Full Year 2017 Financial Results and Provides Corporate Update - Company Continues To Work To Address Clinical Hold On IGNITE DMD - Cambridge, MA, March 29, 2018 - Solid Biosciences Inc. (NASDAQ:SLDB) today reported financial results for the full year

Mar 28, 2018

SOLID BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Solid Biosciences Inc. - SLDB

NEW ORLEANS, March 28, 2018 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit

Mar 14, 2018

Solid Biosciences Announces Clinical Hold On SGT-001 Phase I/II Clinical Trial For Duchenne Muscular Dystrophy

Jan 30, 2018

Solid Biosciences Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Overallotment Option

CAMBRIDGE, Mass., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (NASDAQ:SLDB) (the “Company” or “SLDB”), announced today the closing of its initial public offering of 8,984,375 shares of its common stock, sold by the Company at a public offering price of $16.00 per sha

Jan 30, 2018

Solid Biosciences Announces Closing Initial Public Offering And

Jan 25, 2018